European Union - English - EMA (European Medicines Agency)

glaxo group limited  - retigabine - epilepsy - antiepileptics, - trobalt is indicated as adjunctive treatment of drug-resistant partial-onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate drug combinations have proved inadequate or have not been tolerated.

Malta - English - Medicines Authority

smithkline beecham limited 980, great west road, brentford middlesex tw8 9gs, united kingdom - neisseria meningitidis, polysaccharide group, meningococcal polysaccharide, group w - powder and solvent for solution for injection - neisseria meningitidis polysaccharide group c 50 µg meningococcal polysaccharide group w-135 50 µg - vaccines

Malta - English - Medicines Authority

smithkline beecham limited 980, great west road, brentford middlesex tw8 9gs, united kingdom - neisseria meningitidis, polysaccharide group, meningococcal polysaccharide, group w - powder and solvent for solution for injection - neisseria meningitidis polysaccharide group c 50 µg meningococcal polysaccharide group w-135 50 µg - vaccines

European Union - English - EMA (European Medicines Agency)

glaxo group ltd - retapamulin - impetigo; staphylococcal skin infections - antibiotics and chemotherapeutics for dermatological use - short term treatment of the following superficial skin infections: , impetigo;, infected small lacerations, abrasions or sutured wounds. , see sections 4.4 and 5.1 for important information regarding the clinical activity of retapamulin against different types of staphylococcus aureus. consideration should be given to official guidance on the appropriate use of antibacterial agents.,

Malta - English - Medicines Authority

glaxo group limited - buproprion hydrochloride - modified-release tablet - buproprion hydrochloride 150 mg - psychoanaleptics

Malta - English - Medicines Authority

glaxo group limited - buproprion hydrochloride - modified-release tablet - buproprion hydrochloride 300 mg - psychoanaleptics

European Union - English - EMA (European Medicines Agency)

glaxo group ltd. - amprenavir - hiv infections - antivirals for systemic use - agenerase, in combination with other antiretroviral agents, is indicated for the treatment of protease inhibitor (pi) experienced hiv-1 infected adults and children above the age of 4 years. agenerase capsules should normally be administered with low dose ritonavir as a pharmacokinetic enhancer of amprenavir (see sections 4.2 and 4.5). the choice of amprenavir should be based on individual viral resistance testing and treatment history of patients (see section 5.1).the benefit of agenerase boosted with ritonavir has not been demonstrated in pi nave patients (see section 5.1)

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - meningococcal oligosaccharide group y, quantity: 5 microgram; meningococcal oligosaccharide group c, quantity: 5 microgram; diphtheria crm197 protein, quantity: 16 microgram; meningococcal oligosaccharide group w135, quantity: 5 microgram - injection, solution - excipient ingredients: sodium chloride; water for injections; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate - menveo is indicated for active immunisation of infants and children (from 2 months of age), adolescents and adults to prevent invasive disease caused by neisseria meningitidis serogroups a, c, w-135 and y. the use of this vaccine should be in accordance with official recommendations.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - neisseria meningitidis group b factor h binding protein fusion protein 50ug; neisseria meningitidis group b neisseria adhesin a protein 50ug; neisseria meningitidis group b neisseria heparin binding antigen fusion protein 50ug; neisseria meningitidis sergroup b outer membrane vesicles 25ug;   - suspension for injection - 0.5 ml - active: neisseria meningitidis group b factor h binding protein fusion protein 50ug neisseria meningitidis group b neisseria adhesin a protein 50ug neisseria meningitidis group b neisseria heparin binding antigen fusion protein 50ug neisseria meningitidis sergroup b outer membrane vesicles 25ug   excipient: aluminium hydroxide histidine sodium chloride sucrose water for injection - bexsero is indicated for active immunisation against invasive disease caused by n. meningitidis group b strains. see section 5.1 of the data sheet for information on protection against specific group b strains bexsero is indicated for vaccination of individuals from 2 months of age and older. the use of bexsero should be in accordance with official recommendations.

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - neisseria meningitides group b strain nz98/254; neisseria meningitidis group b fhbp fusion protein; neisseria meningitidis group b nada protein; neisseria meningitidis group b nhba fusion protein - suspension for injection - neisseria meningitides group b strain nz98/254 25 mcg; neisseria meningitidis group b fhbp fusion protein 50 mcg; neisseria meningitidis group b nada protein 50 mcg; neisseria meningitidis group b nhba fusion protein 50 mcg - meningococcus b, outer membrane vesicle vaccine - bexsero is indicated for active immunization of individuals from 2 months of age and older against invasive meningococcal disease caused by neisseria meningitidis group b.